标题
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-02-18
DOI
10.1038/s41573-022-00391-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography
- (2021) Justin S. Sanchez et al. Science Translational Medicine
- Atomic-level differences between brain parenchymal- and cerebrovascular-seeded Aβ fibrils
- (2021) Kathryn P. Scherpelz et al. Scientific Reports
- Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
- (2021) Henrik Zetterberg et al. Molecular Neurodegeneration
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Aducanumab for Alzheimer Disease
- (2021) G. Caleb Alexander et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
- (2021) Jing Qian et al. NEUROLOGY
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
- (2021) Jeffrey Cummings et al. Alzheimers Research & Therapy
- The Problem of Aducanumab for the Treatment of Alzheimer Disease
- (2021) G. Caleb Alexander et al. ANNALS OF INTERNAL MEDICINE
- Aducanumab: What about the Patient?
- (2021) Ronald C. Petersen ANNALS OF NEUROLOGY
- Biomarkers for neurodegenerative diseases
- (2021) Oskar Hansson NATURE MEDICINE
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
- (2021) Stephen Salloway et al. NEUROLOGY
- Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
- (2021) Gil D. Rabinovici NEW ENGLAND JOURNAL OF MEDICINE
- Revisiting FDA Approval of Aducanumab
- (2021) G. Caleb Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Appropriate Use of Accelerated Approval — Aducanumab for Alzheimer’s Disease
- (2021) Billy Dunn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective
- (2021) Billy Dunn et al. JAMA Internal Medicine
- The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease
- (2021) Robert Steinbrook JAMA Internal Medicine
- The β-secretase BACE1 in Alzheimer’s disease
- (2020) Harald Hampel et al. BIOLOGICAL PSYCHIATRY
- Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET
- (2020) Renaud La Joie et al. Science Translational Medicine
- Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
- (2020) Kenta Yoshida et al. Alzheimers Research & Therapy
- Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
- (2020) Sanka Amadoru et al. Alzheimers Research & Therapy
- Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
- (2020) Dominic M Walsh et al. CURRENT OPINION IN NEUROBIOLOGY
- The implications of different approaches to define AT(N) in Alzheimer disease
- (2020) Niklas Mattsson-Carlgren et al. NEUROLOGY
- The coevolution of atomic resolution and whole-brain imaging for tau neurofibrillary tangles
- (2020) Raeann M. Dalton et al. ACS Chemical Neuroscience
- Synergy between amyloid-β and tau in Alzheimer’s disease
- (2020) Marc Aurel Busche et al. NATURE NEUROSCIENCE
- Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease
- (2020) Amy F. T. Arnsten et al. Alzheimers & Dementia
- Predicting future rates of tau accumulation on PET
- (2020) Clifford R Jack et al. BRAIN
- Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment
- (2020) David S. Knopman et al. JAMA Neurology
- Tau PET imaging in neurodegenerative tauopathies—still a challenge
- (2019) Antoine Leuzy et al. MOLECULAR PSYCHIATRY
- Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology
- (2019) Vincent Doré et al. Alzheimers & Dementia
- A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
- (2019) Michael J Pontecorvo et al. BRAIN
- Progressive tau accumulation in Alzheimer’s disease: two-year follow-up study
- (2019) Hanna Cho et al. JOURNAL OF NUCLEAR MEDICINE
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
- (2019) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Target Engagement in an Alzheimer Trial: Crenezumab Lowers Aβ Oligomers in CSF
- (2019) Ting Yang et al. ANNALS OF NEUROLOGY
- Determining clinically meaningful decline in preclinical Alzheimer disease
- (2019) Philip S. Insel et al. NEUROLOGY
- Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults
- (2019) Val J. Lowe et al. NEUROLOGY
- Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography
- (2019) Niklas Mattsson et al. JAMA Neurology
- Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
- (2019) Bernard J. Hanseeuw et al. JAMA Neurology
- Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
- (2019) Sebastian Palmqvist et al. EMBO Molecular Medicine
- Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
- (2019) Gregory Klein et al. Alzheimers Research & Therapy
- Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ
- (2019) William J. Meilandt et al. Alzheimers Research & Therapy
- Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer’s disease brain
- (2018) Wei Hong et al. ACTA NEUROPATHOLOGICA
- Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale
- (2018) Michael Navitsky et al. Alzheimers & Dementia
- Longitudinal tau PET in ageing and Alzheimer’s disease
- (2018) Clifford R Jack et al. BRAIN
- Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
- (2018) Victor L. Villemagne et al. Nature Reviews Neurology
- Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
- (2018) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease
- (2018) Guoqiao Wang et al. STATISTICS IN MEDICINE
- Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode
- (2018) Felix Weber et al. Cell Reports
- The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
- (2018) Holly M. Brothers et al. Frontiers in Aging Neuroscience
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- Imaging the evolution and pathophysiology of Alzheimer disease
- (2018) William Jagust NATURE REVIEWS NEUROSCIENCE
- Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease
- (2018) Andrew J. Aschenbrenner et al. NEUROLOGY
- Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
- (2018) Stephen Salloway et al. Alzheimers Research & Therapy
- Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
- (2018) Renaud La Joie et al. Alzheimers & Dementia
- In vivo staging of regional amyloid deposition
- (2017) Michel J. Grothe et al. NEUROLOGY
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F-18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β-AMYLOID PLAQUE-SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)
- (2016) Michael C. Irizarry et al. Alzheimers & Dementia
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
- (2016) Eric R. Siemers et al. Alzheimers & Dementia
- The Cellular Phase of Alzheimer’s Disease
- (2016) Bart De Strooper et al. CELL
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- Notch signalling in context
- (2016) Sarah J. Bray NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
- (2016) Veronika Logovinsky et al. Alzheimers Research & Therapy
- Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin
- (2016) Mark Ultsch et al. Scientific Reports
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
- (2015) William E. Klunk et al. Alzheimers & Dementia
- Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
- (2015) Osama Sabri et al. Alzheimers & Dementia
- Prevalence of Amyloid PET Positivity in Dementia Syndromes
- (2015) Rik Ossenkoppele et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
- (2015) Willemijn J. Jansen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
- (2015) Enchi Liu et al. NEUROLOGY
- Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
- (2015) Rachelle S Doody et al. Alzheimers Research & Therapy
- Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density
- (2015) Craig Curtis et al. JAMA Neurology
- Primary age-related tauopathy (PART): a common pathology associated with human aging
- (2014) John F. Crary et al. ACTA NEUROPATHOLOGICA
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
- (2014) Eric Karran et al. ANNALS OF NEUROLOGY
- Lessons from a Failed γ-Secretase Alzheimer Trial
- (2014) Bart De Strooper CELL
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
- (2014) Jens Niewoehner et al. NEURON
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Preclinical Alzheimer Cognitive Composite
- (2014) Michael C. Donohue et al. JAMA Neurology
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques
- (2012) Ira Driscoll et al. ACTA NEUROPATHOLOGICA
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
- (2012) Christopher M Clark et al. LANCET NEUROLOGY
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
- (2012) Iryna Benilova et al. NATURE NEUROSCIENCE
- A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
- (2012) Ronald B. DeMattos et al. NEURON
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
- (2011) Susanne Ostrowitzki ARCHIVES OF NEUROLOGY
- Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
- (2011) Heiko Braak et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
- (2010) Delphine Boche et al. ACTA NEUROPATHOLOGICA
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
- (2009) Makoto Higuchi Current Alzheimer Research
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
- (2009) Clifford R Jack et al. LANCET NEUROLOGY
- An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
- (2009) Anna Lord et al. NEUROBIOLOGY OF DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now